- Home
- SENEB vs KROS Comparison
SENEB vs KROS Comparison
Compare SENEB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | KROS |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 655.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SENEB | KROS |
|---|---|---|
| Price | $115.00 | $20.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.20 |
| AVG Volume (30 Days) | 721.0 | ★ 971.2K |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | 1.57 |
| Revenue | ★ $1,606,175,000.00 | $246,718,000.00 |
| Revenue This Year | N/A | $6,876.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.88 | ★ $12.78 |
| Revenue Growth | 8.33 | ★ 37798.31 |
| 52 Week Low | $71.47 | $9.12 |
| 52 Week High | $124.94 | $22.55 |
Technical Indicators
Market Signals| Indicator | SENEB | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 57.46 |
| Support Level | $108.68 | $20.73 |
| Resistance Level | $113.20 | $21.75 |
| Average True Range (ATR) | 0.39 | 1.06 |
| MACD | -1.35 | -0.12 |
| Stochastic Oscillator | 38.87 | 58.36 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.